Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), discusses the most important takeaways from recent guidance on type 1 diabetes from the ADA and European Association for the Study of Diabetes (EASD).
Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), discusses the most important takeaways from recent guidance on type 1 diabetes from the ADA and European Association for the Study of Diabetes (EASD).
Transcript
What are the most important takeaways from the recent guidance on type 1 diabetes from ADA and EASD?
The recent consensus report by the American Diabetes Association and our colleagues at EASD, the European organization, it’s the first comprehensive look at the management of type 1 diabetes, and it covers really soup to nuts. I mean, it covers everything. But just some highlights are newer information about how to make the diagnosis. I think we're all familiar, but the important role of [anti–glutamic acid decarboxylase] anti-gad antibodies, for example, was the first sort of screening antibody to use, and then the role of that versus measuring C-peptide.
It also helps to define what the targets should be for glycemic control for people with type 1 diabetes, and extends that to the ambulatory glucose profile, and how to use that information from a continuous glucose monitor to be able to help manage individuals with diabetes. It then takes time to really go into the importance of mental health, and how that often can be an issue that needs to be addressed for people with type 1 diabetes, and the important role of diabetes self-management, education and support, and what are the topics that need to be covered for people with diabetes.
And then, of course, medical treatment in terms of insulin—the different insulin regimens that one can use, some guidance or dosage, some pluses and minuses of those different regimens. And then even some of the adjunct therapy that has been proposed for people with type 1 diabetes, the data associated with that. So really, it's a comprehensive look at the management of type 1 diabetes that I think clinicians will find really valuable.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More